ClinicalTrials.gg
CompletedNCT05013905APOLLO-CDUpdated Jul 22, 2026Results posted

A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

A Phase 2 interventional study of Tulisokibart and Companion Diagnostic (CDx) in Crohn Disease, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 37 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Crohn Disease by Merck & Co., Inc — 2 open to participants now, 2 under way, 2 of them phase 3. Crohn Disease · Merck & Co., Inc.

Started
2021
the only one that year
Phase 2
Only one
of the 16
Registered
14th of 16
by date

Among the 16 studies in Crohn Disease by Merck & Co., Inc, this one is the only one that started in 2021, is the only one in phase 2, and was the 14th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

2 of the 16 studies in Crohn Disease by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Crohn Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of tulisokibart (MK-7240) in participants with moderately to severely active Crohn's Disease.

After the completion of the 12-week Induction Period, eligible participants have the option to enter an Open-label Extension (OLE) Period for up to 170 weeks.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • APOLLO-CD
  • APOLLO
  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Crohn's disease (CD)
  • Moderately to severely active CD as defined by Crohn's disease activity index (CDAI) score and centrally read endoscopy
  • Must have dependence or have had no response, insufficient response, loss of response and/or intolerance to at least one of the following therapies: corticosteroid, , or an approved anti-tumor necrosis factor (TNF), anti-integrin, or anti-interleukin (IL)12/23
  • Able to provide written and understand and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Women of child bearing potential () and men with female partner of childbearing potential who are unwilling to use two highly effective methods of to avoid pregnancy for the entire study period and up to 12 weeks after the last dose of study drug
  • Diagnosis of ulcerative colitis (UC) or indeterminate colitis
  • CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or illeal involvement
  • Suspected or diagnosed intra-abdominal or perianal abscess at screening
  • Current stoma or need for colostomy or ileostomy
  • Previous small bowel resection with a combined resected length of >100 cm or previous colonic resection of > 2 segments
  • Surgical bowel resection within 3 months before screening
  • Past or current evidence of definite low-grade or high-grade colonic dysplasia not completely removed
  • Participants in the opinion of the investigator are at an unacceptable risk for participation in the study
  • Participants who meet the protocol criteria for important laboratory exclusion criteria
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Induction Tulisokibart

    During the 12-week Induction Period, participants receive tulisokibart administered by intravenous (IV) infusion at 1000 mg at Week 0 and 500 mg at Weeks 2, 6, and 10.

    Biological: Tulisokibart · Diagnostic Test: Companion Diagnostic (CDx)

  • Experimental
    OLE Tulisokibart 100 mg

    After completing the 12-week Induction Period, eligible participants have the option to enter the OLE Period for up to 170 weeks. Participants are randomized into the OLE Period to receive 100 mg tulisokibart by IV infusion every 4 weeks (q4w). At the discretion of the investigator, participants may titrate up to 250 mg Q4W if disease activity is not adequately controlled.

    Biological: Tulisokibart

  • Experimental
    OLE Tulisokibart 250 mg

    After completing the 12-week Induction Period, eligible participants have the option to enter the OLE Period for up to 170 weeks. Participants are randomized into the OLE Period to receive 250 mg tulisokibart by IV infusion q4w.

    Biological: Tulisokibart

Interventions

  • BiologicalTulisokibart

    Tulisokibart administered by IV infusion as directed by the protocol

    Also known as: PRA023, MK-7240

  • Diagnostic testCompanion Diagnostic (CDx)

    PRA023 CDx Genotyping Assay

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of participants who experienced treatment-emergent adverse events (AEs)

    Time frame: Up to approximately 18 weeks

  2. Serious Adverse Events

    Number of participants who experienced serious adverse events (SAEs)

    Time frame: Up to approximately 18 weeks

  3. Adverse Events Leading to Discontinuation

    Number of participants who experienced AEs leading to discontinuation

    Time frame: Up to approximately 12 weeks

  4. Endoscopic Improvement

    Number of participants achieving induction of endoscopic improvement (decrease in simple endoscopy score for Crohn's disease \[SES-CD\] ≥ 50% from Baseline)

    Time frame: Week 12

Secondary outcomes

  1. Clinical Remission

    Number of participants achieving clinical remission, as defined by Crohn's disease activity index \[CDAI\] score \< 150

    Time frame: Week 12

  2. Endoscopic and Clinical Improvement

    Number of participants who achieved a decrease in SES-CD ≥ 50% AND reduction in CDAI ≥ 100 points from Baseline or CDAI\<150

    Time frame: Week 12

  3. Number of Participants Achieving Biomarker and Clinical Composite Improvement

    Biomarker and clinical composite improvement is defined as a decrease by at least 50% in hsCRP or fecal calprotectin from baseline and a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150 in subjects with at least one elevated biomarker at baseline.

    Time frame: Week 12

  4. Normalization of C-reactive Protein

    Number of participants with normalization of hsCRP (as defined by hsCRP \< 5 mg/L), among subjects with elevated concentrations at Baseline, at Week 12

    Time frame: Week 12

  5. Normalization of Fecal Calprotectin

    Number of participants with normalization of fecal calprotectin (fecal calprotectin \< 250 ug/g), among subjects with elevated concentrations at Baseline, at Week 12

    Time frame: Week 12

  6. Clinical Response

    Clinical response is defined as either a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150.

    Time frame: Week 12

  7. Two Component Patient-reported Outcome (PRO-2) Remission

    Number of subjects with PRO-2 remission (defined as average daily abdominal pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than Baseline) at Week 12.

    Time frame: Week 12

  8. Change From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD)

    Assessment of change in simple endoscopy score for Crohn's Disease (SES-CD) from Baseline. Measure Description: The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Baseline and Week 12

  9. Serum Concentration of Tulisokibart

    Blood samples were obtained for PK analysis of the serum concentration of tulisokibart at week 12.

    Time frame: Week 12

  10. Number of Participants Positive for Anti-drug Antibody (ADA)

    Blood samples were collected for the determination of anti-tulisokibart antibodies based on confirmatory assay. The number of participants with confirmed positive anti-tulisokibart antibodies results at any visit during the study is presented.

    Time frame: Up to approximately 12 weeks

  11. Number of Participants With Positive Neutralizing Anti-Bodies (NAB)

    Blood samples were collected for the determination of NAB. The number of participants with positive NAB results at any visit during the study is presented.

    Time frame: Up to approximately 12 weeks

07

Results

Posted Nov 1, 2023

Participant flow

Eligible participants were allocated to the open-label 12-week Induction Period to receive tulisokibart by intravenous infusion. Eligible participants who completed the Induction Period and responded to tulisokibart treatment may have continued into an optional 170-week Open-label Extension (OLE) Period. Participants who entered the OLE Period were randomized to receive tulisokibart at either 100 mg every 4 weeks (q4w) or 250 mg q4w.

Induction Period
Participant flow — Induction Period
MilestoneInduction TulisokibartOLE Tulisokibart 100 mgOLE Tulisokibart 250 mg
Started5500
Completed4900
Not completed600
Withdrew: Lost to follow-up200
Withdrew: Withdrawal by subject400
Open-label Extension Period
Participant flow — Open-label Extension Period
MilestoneInduction TulisokibartOLE Tulisokibart 100 mgOLE Tulisokibart 250 mg
Started01918
Completed092
Not completed01016
Withdrew: Adverse event001
Withdrew: Physician decision010
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject034
Withdrew: Transitioned to a separate long-term extension study0510
Withdrew: Relocated away from the study site010

Outcome measures

PrimaryAdverse Events

Number of participants who experienced treatment-emergent adverse events (AEs)

Time frame:
Up to approximately 18 weeks
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsInduction Tulisokibart
Adverse Events44
PrimarySerious Adverse Events

Number of participants who experienced serious adverse events (SAEs)

Time frame:
Up to approximately 18 weeks
Reported as:
Count of participants · Participants
Serious Adverse Events
ParticipantsInduction Tulisokibart
Serious Adverse Events9
PrimaryAdverse Events Leading to Discontinuation

Number of participants who experienced AEs leading to discontinuation

Time frame:
Up to approximately 12 weeks
Reported as:
Count of participants · Participants
Adverse Events Leading to Discontinuation
ParticipantsInduction Tulisokibart
Adverse Events Leading to Discontinuation2
PrimaryEndoscopic Improvement

Number of participants achieving induction of endoscopic improvement (decrease in simple endoscopy score for Crohn's disease \[SES-CD\] ≥ 50% from Baseline)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Endoscopic Improvement
ParticipantsInduction Tulisokibart
Endoscopic Improvement13
SecondaryClinical Remission

Number of participants achieving clinical remission, as defined by Crohn's disease activity index \[CDAI\] score \< 150

Time frame:
Week 12
Reported as:
Count of participants · Participants
Clinical Remission
ParticipantsInduction Tulisokibart
Clinical Remission27
SecondaryEndoscopic and Clinical Improvement

Number of participants who achieved a decrease in SES-CD ≥ 50% AND reduction in CDAI ≥ 100 points from Baseline or CDAI\<150

Time frame:
Week 12
Reported as:
Count of participants · Participants
Endoscopic and Clinical Improvement
ParticipantsInduction Tulisokibart
Endoscopic and Clinical Improvement9
SecondaryNumber of Participants Achieving Biomarker and Clinical Composite Improvement

Biomarker and clinical composite improvement is defined as a decrease by at least 50% in hsCRP or fecal calprotectin from baseline and a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150 in subjects with at least one elevated biomarker at baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Biomarker and Clinical Composite Improvement
ParticipantsInduction Tulisokibart
Number of Participants Achieving Biomarker and Clinical Composite Improvement17
SecondaryNormalization of C-reactive Protein

Number of participants with normalization of hsCRP (as defined by hsCRP \< 5 mg/L), among subjects with elevated concentrations at Baseline, at Week 12

Time frame:
Week 12
Reported as:
Count of participants · Participants
Normalization of C-reactive Protein
ParticipantsInduction Tulisokibart
Normalization of C-reactive Protein5
SecondaryNormalization of Fecal Calprotectin

Number of participants with normalization of fecal calprotectin (fecal calprotectin \< 250 ug/g), among subjects with elevated concentrations at Baseline, at Week 12

Time frame:
Week 12
Reported as:
Count of participants · Participants
Normalization of Fecal Calprotectin
ParticipantsInduction Tulisokibart
Normalization of Fecal Calprotectin6
SecondaryClinical Response

Clinical response is defined as either a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Clinical Response
ParticipantsInduction Tulisokibart
Clinical Response37
SecondaryTwo Component Patient-reported Outcome (PRO-2) Remission

Number of subjects with PRO-2 remission (defined as average daily abdominal pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than Baseline) at Week 12.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Two Component Patient-reported Outcome (PRO-2) Remission
ParticipantsInduction Tulisokibart
Two Component Patient-reported Outcome (PRO-2) Remission27
SecondaryChange From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD)

Assessment of change in simple endoscopy score for Crohn's Disease (SES-CD) from Baseline. Measure Description: The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD)
score on a scaleInduction Tulisokibart
Change From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD)-2.6 ± 4.32
SecondarySerum Concentration of Tulisokibart

Blood samples were obtained for PK analysis of the serum concentration of tulisokibart at week 12.

Time frame:
Week 12
Reported as:
Mean · ng/mL
Serum Concentration of Tulisokibart
ng/mLInduction Tulisokibart
Serum Concentration of Tulisokibart88199.1 ± 43811.21
SecondaryNumber of Participants Positive for Anti-drug Antibody (ADA)

Blood samples were collected for the determination of anti-tulisokibart antibodies based on confirmatory assay. The number of participants with confirmed positive anti-tulisokibart antibodies results at any visit during the study is presented.

Time frame:
Up to approximately 12 weeks
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-drug Antibody (ADA)
ParticipantsInduction Tulisokibart
Number of Participants Positive for Anti-drug Antibody (ADA)8
SecondaryNumber of Participants With Positive Neutralizing Anti-Bodies (NAB)

Blood samples were collected for the determination of NAB. The number of participants with positive NAB results at any visit during the study is presented.

Time frame:
Up to approximately 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Positive Neutralizing Anti-Bodies (NAB)
ParticipantsInduction Tulisokibart
Number of Participants With Positive Neutralizing Anti-Bodies (NAB)8

Adverse events

Collected over Up to approximately 43 months (duration over which AEs were assessed at the participant level). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Tulisokibart0/55 (0%)9/55 (16.4%)33/55 (60%)
Induction Tulisokibart → OLE Tulisokibart 100 mg0/19 (0%)4/19 (21.1%)17/19 (89.5%)
Induction Tulisokibart → OLE Tulisokibart 250 mg0/18 (0%)4/18 (22.2%)16/18 (88.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventInduction TulisokibartInduction Tulisokibart → OLE Tulisokibart 100 mgInduction Tulisokibart → OLE Tulisokibart 250 mg
Crohn's diseaseGastrointestinal disorders4/553/192/18
Small intestinal obstructionGastrointestinal disorders0/552/191/18
Diarrhoea infectiousInfections and infestations0/550/191/18
Transient ischaemic attackNervous system disorders0/550/191/18
Atrial fibrillationCardiac disorders0/551/190/18
Small intestinal perforationGastrointestinal disorders0/551/190/18
HaemoptysisRespiratory, thoracic and mediastinal disorders0/551/190/18
Abdominal painGastrointestinal disorders2/550/190/18
Anal abscessInfections and infestations1/550/190/18
COVID-19 pneumoniaInfections and infestations1/550/190/18
Most frequent other events
Showing 10 of 102
Most frequent other events
EventInduction TulisokibartInduction Tulisokibart → OLE Tulisokibart 100 mgInduction Tulisokibart → OLE Tulisokibart 250 mg
Crohn's diseaseGastrointestinal disorders3/557/196/18
Upper respiratory tract infectionInfections and infestations2/555/193/18
GastroenteritisInfections and infestations0/551/194/18
VomitingGastrointestinal disorders2/550/193/18
Urinary tract infectionInfections and infestations5/553/193/18
COVID-19Infections and infestations7/553/192/18
HeadacheNervous system disorders2/553/192/18
Anal fistulaGastrointestinal disorders0/552/192/18
BronchitisInfections and infestations1/550/192/18
Clostridium difficile infectionInfections and infestations0/550/192/18

Baseline characteristics

Age, Customized
Age, Customized(Participants)Induction Tulisokibart
Age (years) — 18-44 years37
Age (years) — 45-64 years13
Age (years) — 65+ years5
Sex: Female, Male
Sex: Female, Male(Participants)Induction Tulisokibart
Female21
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction Tulisokibart
Hispanic or Latino1
Not Hispanic or Latino51
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction Tulisokibart
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White48
More than one race0
Unknown or Not Reported4
Weight
Weight(kg)Induction Tulisokibart
Mean77.6 ± 20.6
Duration of Disease (years)
Duration of Disease (years)(years)Induction Tulisokibart
Mean10.29 ± 9.27
Baseline Crohn's disease activity index (CDAI) Score
Baseline Crohn's disease activity index (CDAI) Score(score)Induction Tulisokibart
Mean317.9 ± 67.2
Number of Prior Exposure to Biologic Therapy
Number of Prior Exposure to Biologic Therapy(Participants)Induction Tulisokibart
Biologic Naive16
1 Prior Biologic10
2 Prior Biologics10
>=3 Prior Biologics19

3 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • Prometheus Biosciences Selected Site
    Los Angeles, California 90045, United States
  • Prometheus Biosciences Selected Site
    Los Angeles, California 90048, United States
  • Prometheus Biosciences Selected Site
    Liberty, Kansas 64098, United States
  • Prometheus Biosciences Selected Site
    Chesterfield, Michigan 48047, United States
  • Prometheus Biosciences Selected Site
    Ypsilanti, Michigan 48197, United States
  • Prometheus Biosciences Selected Site
    St Louis, Missouri 63141, United States
  • Prometheus Biosciences Selected Site
    Lebanon, New Hampshire 03756, United States
  • Prometheus Biosciences Selected Site
    New York, New York 10065, United States
  • Prometheus Biosciences Selected Site
    Garland, Texas 75044, United States
  • Prometheus Biosciences Selected Site
    Lubbock, Texas 79410, United States
  • Prometheus Biosciences Selected Site
    Lubbock, Texas 79424, United States
  • Prometheus Biosciences Selected Site
    San Antonio, Texas 78229, United States
  • Prometheus Biosciences Selected Site
    Southlake, Texas 78229, United States
  • Prometheus Biosciences Selected Site
    Tyler, Texas 75702, United States
  • Prometheus Biosciences Selected Site
    Bellevue, Washington 98004, United States
  • Prometheus Biosciences Selected Site
    Tacoma, Washington 98405, United States
  • Prometheus Biosciences Selected Site
    Bankstown, New South Wales 2146, Australia
  • Prometheus Biosciences Selected Site
    Woolloongabba, Queensland 4102, Australia
  • Prometheus Biosciences Selected Site
    Adelaide, South Australia 5000, Australia
  • Prometheus Biosciences Selected Site
    Leuven, 3000, Belgium
  • Prometheus Biosciences Selected Site
    Liège, 4000, Belgium
  • Prometheus Biosciences Selected Site
    London, Ontario N6A 5W9, Canada
  • Prometheus Biosciences Selected Site
    Brno, Czechia
  • Prometheus Biosciences Selected Site
    Slaný, 274 01, Czechia
  • Prometheus Biosciences Selected Site
    Clichy, 92110, France
  • Prometheus Biosciences Selected Site
    Nice, 06202, France
  • Prometheus Biosciences Selected Site
    Saint-Priest-en-Jarez, 42270, France
  • Prometheus Biosciences Selected Site
    Vandœuvre-lès-Nancy, 54511, France
  • Prometheus Biosciences Selected Site
    Tbilisi, Georgia
  • Prometheus Biosciences Selected Center
    Krakow, 31-501, Poland
  • Prometheus Biosciences Selected Site
    Rzeszów, 35-326, Poland
  • Prometheus Biosciences Selected Site
    Sopot, 81-756, Poland
  • Prometheus Biosciences Selected Site
    Torun, 87-100, Poland
  • Prometheus Biosciences Selected Center
    Warsaw, 00-635, Poland
  • Prometheus Biosciences Selected Site
    Warsaw, 03-580, Poland
  • Prometheus Biosciences Selected Center
    Warsaw, 52-416, Poland
  • Prometheus Biosciences Selected Site
    Wroclaw, 52-416, Poland
09

References and documents

Publications

  • Feagan BG, Sands BE, Siegel CA, Dubinsky MC, Longman RS, Sabino J, Laurent O, Luo A, Lu J, Nguyen DD, Munoz-Elias EJ, Llewellyn H, Wang Y, Jang I, Bilsborough J, Marchelletta R, Towfic F, Yen M, Anderson JK, DuVall A, Kierkus J, Woynarowski M, Al Kharrat H, Targan SR, McGovern DPB. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol. 2025 Aug;10(8):715-725. doi: 10.1016/S2468-1253(25)00071-8. Epub 2025 May 30. PubMed 40456235 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Sep 2022, 13 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Aug 19, 2021
StartActual
Jul 28, 2021
Primary completionActual
Sep 23, 2022
CompletionActual
May 27, 2025
Results first posted
Nov 1, 2023
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05013905
Responsible party
Sponsor
First posted
Aug 19, 2021
Start date
Jul 28, 2021
Primary completion
Sep 23, 2022
Completion
May 27, 2025
Results posted
Nov 1, 2023
Last update
Jul 22, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion